CONTENTS VOL. 14, 1996

Special issue

Phase I anticancer drug development in pediatrics
Steven Weitman and Charles Pratt, guest editors

New drug development for pediatric oncology – S. Weitman, L. Carlson, C.B. Pratt 1–10

Pediatric drug development: a perspective from the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI) – M. Smith, P.T.C. Ho 11–22

Phase I trials in paediatric oncology – the European perspective – E.J. Estlin, S. Ablett, D.R. Newell, I.J. Lewis, L. Lashford, A.D.J. Pearson 23–32

The importance of Phase I/II trials in pediatric oncology – C.A. MacArthur, T. Vietti 33–35

Topoisomerase I interactive drugs in children with cancer – C.F. Stewart, W.C. Zamboni, W.R. Crom, A. Gajjar, R.L. Heideman, W.L. Furman, W.H. Meyer, P.J. Houghton, C.B. Pratt 37–47

New microtubular agents in pediatric oncology – N.L. Seibel, G.H. Reaman 49–54

Multidrug resistance in pediatric oncology – J.F. Kuttesch, Jr. 55–67

Pharmacologic strategies for the treatment of meningeal malignancy – S.M. Blaney, D.G. Poplack 69–85

Gene therapy in pediatric oncology – E. Benaim, B.P. Sorrentino 87–99

Folate, antifolates, and folate analogs in Pediatric Oncology – M.C. Hum, B.A. Kamen 101–111

Instructions for authors 113–114

Lead Article

Active vs. passive resistance, dose-response relationships, high dose chemotherapy, and resistance modulation: a hypothesis – D.J. Stewart, G.P. Raaphorst, J. Yau, A.R. Beaubien 115–130

Preclinical Studies

Antitumor activity of combretastatin-A4 phosphate, a natural product tubulin inhibitor – R.T. Dorr, K. Dvorakova, K. Snead, D.S. Alberts, S.E. Salmon, G.R. Pettit 131–137

Morpholinylanthracyclines: cytotoxicity and antitumor activity of differently modified derivatives – M. Ripamonti, L. Capolongo, G. Melegaro, C. Gornati, A. Bargiotti, M. Caruso, M. Grandi, A. Suarato 139–146

Docetaxel serum protein binding with high affinity to alpha$_1$-acid glycoprotein – S. Urien, J. Barré, C. Morin, A. Paccaly, G. Montay, J.-P. Tillement 147–151

Efficacy of 5′-nor-anhydrovinblastine (vinorelbine), against freshly explanted clonogenic human tumor cells *in vitro* – I. Djuanda, H. Depenbrock, R. Peter, T. Block, G. Pohlmann, J. Rastetter, A.-R. Hanauske 153–159

Efficacy of HMAF (MGI-114) in the MV522 metastatic lung carcinoma xenograft model nonresponsive to traditional anticancer agents – M.J. Kelner, T.C. McMorris, L. Estes, W. Wang, K.M. Samson, R. Taetle 161–167

In vitro cytotoxicity of S16020-2, a new olivacine derivative – S. Léonce, V. Perez, M.-R. Casabianca-Pignede, M. Anstett, E. Bisagni, A. Pierré, G. Atassi 169–180

Purity determinations in the bulk drug of the novel indoloquinone antitumor agent EO9 – J.D. Jonkman-de Vries, J.J. Kettenes-van den Bosch, R.E.C. Henrar, A. Bult, J.H. Beijnen 181–191

Phase I Studies

Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer – S. Wojtowicz-Praga, J. Low, J. Marshall, E. Ness, R. Dickson, J. Barter, M. Sale, P. McCann, J. Moore, A. Cole, M.J. Hawkins 193–202

Phase II Studies

Phase II trial of docetaxel in patients with recurrent malignant glioma: a study of the National Cancer Institute of Canada Clinical Trials Group – P. Forsyth, G. Cairncross, D. Stewart, M. Goodyear, N. Wainman, E. Eisenhauer 203–206

A phase II study of weekly oral methotrexate and zidovudine (AZT) in advanced adenocarcinoma of the pancreas and hepatocellular carcinoma – K.D. Miller, P.J. Loehrer, R. Gonin, G. Weber, R. Ansari, W. Pletcher, J. McClean, C.H. Spiridonidis, J. Mortimer 207–212

Phase II study of elsamitrucin (BMY-28090) for the treatment of patients with refractory/relapsed non-Hodgkin's lymphoma – S.L. Allen, L.P. Schacter, S.M. Lichtman, R. Bukowski, D. Fusco, M. Hensley, P. O'Dwyer, A. Mittelman, B. Rosenbloom, S. Huybensz 213–217

A phase II trial of ilmofosine in non-small cell bronchogenic carcinoma – P.V. Woolley, C.J. Schultz, G.I. Rodriguez, R.A. Gams, K.W. Rowe Jr., M.L. Dadey, D.D. Von Hoff, J.J. McPhillips 219–222

Phase II study of Mitonafide in advanced and relapsed colorectal cancer – A. Abad, C. Grávalos, A. Font, F. Molina, M.T. Díaz-Puente, X. Fabregat, A. Benavides, M. Martín 223–225

Pharmacokinetic profile of Mitoguazone (MGBG) in patients with AIDS related non-Hodgkin's lymphoma – J. Rizzo, A.M. Levine, G.R. Weiss, T. Pearce, M. Kraynak, R. Mueck, S. Smith, D.D. Von Hoff, J.G. Kuhn 227–234

Brief Report

Octreotide as first-line treatment for women with metastatic breast cancer – J.N. Ingle, C.G. Kardinal, V.J. Suman, J.E. Krook, A.K. Hatfield 235–237

Instructions for authors 239–240

Special issue

Novel anticancer agents for solid tumors – A tribute to Dr. Jerry B. Grindey
S.D. Harrison, E. Mihich and H.L. Pearce, guest editors

A tribute to Dr. Gerald Burr Grindey, 1940–1993 – E. Mihich, R.G. Moran, C.A. Nichol 241–242

Comparison of the antitumor activity of gemcitabine and ara-C in a panel of human breast, colon, lung and pancreatic xenograft models – R.L. Merriman, L.W. Hertel, R.M. Schultz, P.J. Houghton, J.A. Houghton, P.G. Rutherford, L.R. Tanzer, G.B. Boder, G.B. Grindey 243–247

Curative chemotherapy for acute myeloid leukemia: the development of high-dose ara-C from the laboratory to bedside – R.L. Capizzi 249–256

Gemcitabine and radiosensitization in human tumor cells – D.S. Shewach, Th.S. Lawrence 257–263

Activity of gemcitabine in a human tumor cloning assay as a basis for clinical trials with gemcitabine – D.D. Von Hoff 265–270

Antitumor diarylsulfonylureas: novel agents with unfulfilled promise – P.J. Houghton, J.A. Houghton 271–280

A simplified and efficient synthesis of 5,10-dideaza-5,6,7,8-tetrahydrofolic acid (DDATHF) – E.C. Taylor, R. Chaudhari, K. Lee 281–285

Biochemistry and pharmacology of glycinamide ribonucleotide formyltransferase inhibitors: LY309887 and lometrexol – L.G. Mendelsohn, C. Shih, R.M. Schultz, J.F. Worzalla 287–294

AG2034: a novel inhibitor of glycinamide ribonucleotide formyltransferase – T.J. Boritzki, C.A. Barlett, C. Zhang, E.F. Howland, S.A. Margosiak, C.L. Palmer, W.H. Romines, R.C. Jackson 295–304

Tomudex™ (ZD1694): from concept to care, a programme in rational drugs discover – A.L. Jackman, F.T. Boyle, K.R. Harrap 305–315

Exploitation of folate and antifolate polyglutamylation to achieve selective anticancer chemotherapy – J.J. McGuire, T. Tsukamoto, B.P. Hart, J.K. Coward, T.I. Kalman, J. Galivan 317–323

A Phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid – S. Laohavinij, S.R. Wedge, M.J. Lind, N. Bailey, A. Humphreys, M. Proctor, F. Chapman, D. Simmons, A. Oakley, L. Robson, L. Gunbrell, G.A. Taylor, H.D. Thomas, A.V. Boddy, D.R. Newell, A.H. Calvert 325–335

Epilogue – S. Harrison 337

Instructions for authors 339–340

Preclinical Studies

Cellular transport of CI-980 – K.E. Hook, S.A. Przybranowski, W.R. Leopold 341–347

Preclinical antitumor activity of CI-994 – P. Mucci LoRusso, L. Demchik, B. Foster, J. Knight, M.-C. Bissery, L.M. Polin, W.R. Leopold III, T.H. Corbett 349–356

Effects of 13-hydroxy SM5887 in combination with other anticancer agents on human tumor cell lines – T. Takagi, Y. Yazawa, K. Suzuki, Y. Yamauchi, Y. Kano 357–363

Murraya koenigii and *Brassica juncea* – Alterations on lipid profile in 1-2 dimethyl hydrazine induced colon carcinogenesis – B.A. Khan, A. Abraham, S. Leelamma 365–369

Phase I Studies

Clinical phase I and pharmacokinetic trial of vinorelbine administered as single intravenous bolus every 21 days in cancer patients – T. Schilling, H.H. Fiebig, S. Kerpel-Fronius, B. Winterhalter, P. Variol, P. Tresca, B. Heinrich, A.-R. Hanauske 371–378

Clinical and pharmacokinetic phase I trial of oral dimethylaminoetoposide (NK611) administered for 21 days every 35 days – I. Raßmann, H. Schrödel, T. Schilling, M. Zucchetti, A. Kaeser-Fröhlich, J. Rastetter, A.-R. Hanauske 379–386

Phase I trial of recombinant platelet factor 4 (rPF4) in patients with advanced colorectal carcinoma – N. Belman, E.M. Bonnem, H.A. Harvey, A. Lipton 387–389

Phase II Studies

13-Cis-retinoic acid and interferon alpha-2a in patients with advanced esophageal cancer: a phase II trial – C.F. Slabber, G. Falkson, W. Burger, L. Schoeman 391–394

A phase II trial of a differentiating agent (tRA) with cisplatin-VP 16 chemotherapy in advanced non-small cell lung cancer – R. Thiruvengadam, J.O. Atiba, S.H. Azawi 395–401

Evaluation of topotecan in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: a phase II Southwest Oncology Group study – R.E. Smith, D. Lew, G.I. Rodriguez, S.A. Taylor, D. Schuller, J.F. Ensley 403–407

A phase II trial of amonafide, caracemide, and homoharringtonine in the treatment of patients with advanced renal cell cancer – R.S. Witte, P. Hsieh, P. Elson, M.M. Oken, D.L. Trump 409–413

Phase II study of mitonafide in non-small cell lung cancer (NSCLC) – A. Casado, R. Rosell, R. García-Gómez, E. Díaz-Rubio, G. Pérez-Manga, A. Font, A. Benavides, M. Martín 415–417

Phase II trial of low-dose N-(phosphonacetyl)-disodium L-aspartic acid and high-dose 24-hour infusional 5-Fluorouracil in advanced gastric adenocarcinoma: A Southwest Oncology Group study – R.L. Martino, T.R. Fleming, L.M. Morell, B. Ardalan, S.P. Richman, J.S. Macdonald 419–421

Contents Volume 14, 1996 423–426

Author Index 427–429

Instructions for Authors 431–432